ASMB vs. CPIX, OMER, NKTR, CUE, VTVT, CARM, DERM, CRVS, YS, and ANEB
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Cumberland Pharmaceuticals (CPIX), Omeros (OMER), Nektar Therapeutics (NKTR), Cue Biopharma (CUE), vTv Therapeutics (VTVT), Carisma Therapeutics (CARM), Journey Medical (DERM), Corvus Pharmaceuticals (CRVS), YS Biopharma (YS), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
Assembly Biosciences has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -15.87%. Cumberland Pharmaceuticals' return on equity of 6.84% beat Assembly Biosciences' return on equity.
Assembly Biosciences received 54 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 59.21% of users gave Assembly Biosciences an outperform vote while only 45.28% of users gave Cumberland Pharmaceuticals an outperform vote.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Assembly Biosciences has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
In the previous week, Cumberland Pharmaceuticals had 19 more articles in the media than Assembly Biosciences. MarketBeat recorded 42 mentions for Cumberland Pharmaceuticals and 23 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of -0.01 beat Cumberland Pharmaceuticals' score of -0.22 indicating that Assembly Biosciences is being referred to more favorably in the media.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 4.1% of Assembly Biosciences shares are held by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Assembly Biosciences beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
